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Abstract
Cell death is clearly an important factor in development, homeostasis, pathology and in aging, but medical
efforts based on controlling cell death have not become major aspects of medicine. There are several rea-
sons why hopes have been slow to be fulfilled, and they present indications for new directions in research.
Most effort has focused on the machinery of cell death, or the proximate effectors of apoptosis and their
closely associated and interacting proteins. But cells have many options other than apoptosis. These include
autophagy, necrosis, atrophy and stepwise or other alternate means of self-disassembly. The response of a
cell to a noxious or otherwise intimidating signal will depend heavily on the history, lineage and current sta-
tus of the cell. Many metabolic and other processes adjust the sensitivity of cells to signals, and viruses
aggressively attempt to regulate the death of their host cells. Another complicating factor is that many death-
associated proteins may have functions totally unrelated to their role in cell death, generating the possibility
of undesirable side effects if one interferes with them. In the future, the challenge will be more to understand
the challenge to the cell from a more global standpoint, including many more aspects of metabolism, and
work toward alleviating or provoking the challenge in a targeted fashion.
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Cell death is important
in medicine
There are now over 200,000 publications listed by
the United States Library of Medicine for the topics
‘apoptosis OR cell death OR programmed cell death’
and a new publication appears every 24 min. One 
could therefore reasonably conclude that this group
of topics would be a major aspect of clinical medicine.
By three criteria, this is true: we are well accustomed
to the idea that, with the exception of the targets of
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natural killer cells, very few cells are murdered. By far
the majority commit suicide under specific condi-
tions. Second, many developmental and chronic dis-
eases can be traced to genetic or other problems
with genes known to influence cell death, such as the
cancers that arise because of mutations or transloca-
tions of anti-apoptotic genes such as bcl-2 or dam-
age surveillance apoptosis activators such as p53,
and autoimmune diseases associated with mutations
of Fas or Fas Ligand. Third, in many diseases even
when the origin is not inherently genetic, the patho-
logical state is characterized by substantial apoptosis
or other form of cell death. Thus neurodegenerative
diseases, HIV-AIDS, inflammatory or autoimmune
disease, infarct or ischaemia, several types of viral
infection, infertility and many other pathological or
undesirable situations are described as deriving from
abnormalities in the expected pattern of cell death, or
even as being diseases of deranged cell death.These
topics are the subject of numerous reviews, including
the following excellent and most recent ones [1–9].
The importance of cell death was first recognized
in developing embryos. Developmental biologists
realized that cell death must be under genetic regu-
lation as deregulated cell death generated many
mutant phenotypes including both developmental
and adult abnormalities. Complete blockage of cell
death is lethal in most embryos (though not
Caenorhabditis); and cell death starts at very stages
of development – as early as eight cell stage – and is
essential for organogenesis [10–13]. Half to two-thirds
of developing neurons die before the completion of
development and huge numbers of T- and B-lympho-
cytes likewise undergo developmental selection.
Though the numbers are not so massive, cell death
can be seen in almost all other developing organs.
Some of the best-known examples, such as the
cornea [14–16] and interdigital tissues of the limbs of
amniotes that do not have webs, are known primari-
ly because their accessibility has allowed experimen-
tation and evaluation [17–23]; but the sculpting of all
complex organs, particularly those such as the kid-
ney in which structure is vital for function, involves
cell death. Sexual differentiation begins with elimina-
tion of either the Müllerian or Wolffian ducts and
includes several other instances of controlled cell
death throughout life.
Cell death is likewise important in normal cellular
and organismic homeostasis. Billions of cells die
every day. By far the largest number are red blood
cells (about 250 x 109/day), the death of which has
been described as a delayed, stepwise death (first,
elimination of nucleus and mitochondria; later,
though still controlled, phagocytosis of the stiffening,
aged erythrocyte) [24–28]. Replacement of skin and
digestive tract lining run a close second, with several
diseases being related to differences in the kinetics
of turnover of epithelial cells. Responsive cells of the
immune system must down-regulate after the initial
stimulus has been resolved. Even in the liver, the loss
of one cell in 1000 every day, in what is described as
‘normal turnover’, adds up to approximately
180,000,000 cells lost per day [29]. Both lack of and
inappropriate level or timing of cell death can cause
major havoc.
Why do we not have a medicine
based on apoptosis?
Nevertheless, several attempts to treat symptoms or
disease by manipulating cell death have not suc-
ceeded. Among these are efforts to inhibit or activate
caspases, to provide supporting trophic factors, to
initiate type II or cell surface receptor-induced apop-
tosis, to correct genetic defects that lead to apopto-
sis by targeting the products of the altered genes,
and to exploit the differences between the availabili-
ties of cell death pathways in malignant and normal
cells. By and large, these efforts up to now have
looked far more promising in the laboratory than they
have proven to be in patients, although there is still
much potential [30].
What might be the cause of such a discrepancy?
There are several reasons why our understanding of
mechanisms of cell death and the vigorous efforts of
many laboratories, research institutions and biotech
companies, specific applications have not yet
reached the clinical horizon. Among the most impor-
tant of these reasons are the facts that (1) in most
instances of pathology, the source of the problem is
not the machinery of apoptosis, which remains intact,
but rather its regulation; (2) Although the machinery
stays intact, the choice of machinery or path can
change the measurement or the outcome; (3) our
current understanding that a cell will take alternate
paths if one is blocked makes it more difficult to do
directed drug therapy since attacking and disabling
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one part of the machinery can be overcome by turn-
ing on another path; (4) to specifically target a drug
to a specific type of cell is a far more challenging task
than to create an inhibitor; (5) many researchers
neglect the fact that the death of a cell is a symptom
and outcome of a more pervasive problem and (6)
when conditions become intolerable for survival-meaning
chemical, osmotic, oxidative or other damage to cell or
organelle membranes, failure of adenosine triphos-
phate (ATP)-generating systems, subversion of
resources toward virus production or precipitation of
proteins because of inappropriate pH, ion composi-
tion or temperature-cells will succumb whether or not
their preferred method of suicide is available. We will
consider each of these issues in turn.
The machinery of cell death
Studies using mutant animals in which lack of cell
death could be overcome with the use of drugs [31]
or activation or deactivation of specific genes [32, 33]
led to the idea that a cell death machinery exists in
all cells. The term ‘machinery’ is used in two senses:
in the larger sense, it refers to the ability of a cell to
generate and interpret signals that tell it to die as well
as to the activation of the specific enzymes, primari-
ly caspases, that kill it. In a narrower sense, ‘cell
death machinery’ refers only to the caspase cascade
and those molecules that directly interact with either
the extrinsic or intrinsic pathway. Here, we refer to the
machinery in the narrow sense to emphasize that the
interaction, engagement and activation of this machin-
ery is very complex and only crudely understood.
The brilliant hypothesis and generalization that a
pattern of cell death was common to many organ-
isms, cell types and situations was quickly validated
and led both to relatively easy and reliable means of
detecting apoptosis and to identification of the mech-
anisms that created the identifiable morphology and
biochemical characteristics of apoptosis. The process
was so general and so extensible – ranging from
nematode worms to humans – that (following the
binary mindset common to most styles of thinking)
the perception arose that all cells die either in a con-
trolled apoptotic death or by uncontrolled necrotic
death. Today we recognize that the issue is more
subtle, as the history, descent, stage of differentiation
and environment of a cell can alter its sensitivity to
death or the manner in which it dies. However, the
paths of apoptosis are so common that they are fre-
quently if incorrectly believed to be an unequivocal or
exclusive criterion for cell death. Thus, most of the
criteria by which we identify cell death in reality are
markers of apoptosis and derive directly or indirectly
from the activation of effector caspases. These mark-
ers include direct assessment of the activation of
(usually) caspase 3; shrinkage and blebbing of cells;
margination of chromatin and fragmentation of nuclei
and exteriorization of phosphatidylserine while the
plasma membrane retains osmotic integrity. The
importance of this process is established because
there are many mutations, knockouts, transfections,
translocations and other genetic alterations either
directly to the machinery of cell death (caspase cas-
cade and membrane-associated or mitochondrial
components leading to its activation) or to important
regulators of the threshold at which the cascade is
activated, such as the pro- and anti-apoptotic mem-
bers of the bcl-2 family of regulators, Most of these,
whether spontaneously appearing in humans or
engineered in rodents, produce phenotypes or dis-
eases consistent with maladjusted patterns of apop-
tosis. Similarly, somatic mutation of regulators of
apoptosis such as p53 considerably darkens progno-
sis in many cancers. Thus it is clear that regulation of
cell death is an important factor in at least two class-
es of cancer, and many researchers have associated
other severe diseases with imperfect regulation of
cell death. For instance, excess cell death character-
izes several neurodegenerative diseases and con-
genital neural anomalies, and autoimmune diseases
may arise either from stimulation of T cells by apop-
totic fragments resulting from chronic inflammation or
from failure of the immune system to down-regulate
after stimulation (meaning insufficient death of the
reacting cells). However, in many or most situations
that have sufficient impact to warrant our attention,
either the cell death machinery is intact but the
threshold at which it is activated has changed – this
is true for the B cell lymphomas and p53-exacerbat-
ed digestive tract tumours – or the machinery is
appropriately activated because of a proximate
cause such as viral infection or oxidative or other
injury to the cell. In both instances, direct attack on
the machinery, for instance caspase 3, does not alle-
viate the primary source of the problem. It becomes
very difficult to activate caspase 3 in cells possess-
ing a bcl-2 translocation or mutation in p53 without
J. Cell. Mol. Med. Vol 11, No 6, 2007
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affecting normal cells. Alternatively, while an autoim-
mune disease may possibly have arisen because of
an accumulation of T cells, itself perhaps of genetic
origin, excess cell death in inflammation derives from
the inflammation rather than from a genetic defect,
and the proximate cause of the inflammation must be
addressed. In neurodegenerative disease, cells die
after prolonged agony because they are subject to
chronic metabolic or other stress. Relieving the stress
is likely to be more effective than preventing death. In
any event, mere survival is not the criterion. Cells may
survive in an atrophied state, for instance when they
are deprived of growth factors, without being function-
al. Nerve cells may have minimal resting potential and
be incapable of generating or propagating an action
potential. Other cells, subjected to lethal toxins such
as anti-mitotics, may persist for extended periods of
time, existing as ‘zombies’ and incapable of future
division [34, 35] yet not undergoing apoptosis.
Thus, apoptosis by itself is neither pathology nor a
healthy physiological situation. There is modest evi-
dence that in a few specific, acute situations direct
targeting of the cell death machinery may have
value. For instance, in an infarct most of the hypoxic
cells reversibly accumulate lactic acid and ultimately
fail only hours later or, if circulation is re-established,
shortly after reperfusion begins. In the latter case, the
osmotic disequilibrium triggers either immediate
osmotic lysis (necrosis) or the stressed cells under-
go apoptosis a bit later. If this apoptosis is prevented,
many of the cells ultimately survive and the size of
the infarct may be drastically reduced, with substan-
tial clinical benefit. Note however that this is an acute
situation in which the stress is ultimately relieved.
Delaying apoptosis buys time, and the critical issue
is to prevent the suicide until the condition can be
corrected, rather like delivering oxygen or water
through a tube to an individual trapped in a collapsed
building or mine.Where the stress is chronic, unknown
or generic, preventing apoptosis may simply post-
pone the inevitable, or brute-force approaches, such
as injecting caspase inhibitors, may seriously com-
promise healthy cells or have other untoward effects.
The ‘untoward effects’ come in at least three cate-
gories: cells have many options other than apoptosis;
the response of a cell depends heavily on its history,
lineage and current status; and proteins now
assumed to be cell death proteins may in fact have
‘day jobs’ or multiple functions not appreciated by the
researcher or physician.
Cells have many options 
other than apoptosis
It stands to reason that one does not need an instruc-
tion manual to die. The biological consequence of
this platitude is that absence of the phenotype of
apoptosis is not necessarily survival. In the laborato-
ry, cells exposed to staurosporin, cycloheximide,
ethanol or any of several chemotherapeutic drugs
used experimentally may not, under certain circum-
stances, manifest apoptosis and they may survive a
few hours longer than other cells, but they surely will
die. Likewise, in an experimental or clinical situation,
chemical or genetic blockage of the central machin-
ery of apoptosis may yield decreased apoptosis but
not necessarily increased survival of cells. We may
have learned something about apoptosis without
learning about the pathology. What most commonly
happens is that the cell reverts to an alternative path
of self-destruction.
There are many alternative paths. Typically, a
large, cytoplasm-rich, post-mitotic or poorly mitotic
cell such as a mammary epithelial cell has a big
problem eliminating its cytoplasm, whereas a small,
short-lived, highly mitotic cell subject to many muta-
genic situations is more threatening because of its
potentially damaged or mutated DNA. Thus apopto-
sis, with its rapid and complete destruction of DNA,
is easily and promptly activated in cells of haematopoi-
etic lineage, while mammary epithelial cells and oth-
ers undertake massive autophagy. In insects, during
metamorphosis the bulk of the larval tissue is
destroyed, and cell death is easily timed and is toler-
ably synchronous. Here, apoptosis is an inconspicu-
ous aspect of the cell death. During metamorphosis,
the first 90% of the period during which the cell is
dying is occupied by autophagic processes, with no
activation of caspases, margination of chromatin,
fragmentation of DNA or exteriorization of phos-
phatidyl serine. At the very end, when almost all cyto-
plasm has been consumed, one encounters evi-
dence of apoptosis: condensation and margination of
chromatin, fragmentation of DNA into nucleosome
ladders, exteriorization of phosphatidyl serine and
(though insect caspases differ from mammalian cas-
pases and are harder to document) apparent activa-
tion of a caspase (Fig. 1). This is what we and others
have called autophagic cell death, but it appears today
in a different light. Although in the metamorphosing
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insect nutritional supplies are good (the adult or
imaginal tissues are growing rapidly) the larval tis-
sues do not thrive and undergo a type of autophagy
that is normally associated with starving cells, cells
deprived of trophic hormones or cells that have suf-
fered substantial damage to organelles. It appears
that, as in the case in many laboratory experiments,
the cell dies only when autophagy fails to sustain it
beyond a point of no return. In PC-12 cells deprived
of nerve growth factor, the point of no return is the
autophagic destruction of all their mitochondria. We
do not know the limitation of the larval insect cells.
Their tracheae (insect direct-to-cell breathing tubes)
collapse and mitochondria are subjected to autophagy,
suggesting an energy limitation, but they retain suffi-
cient ATP ultimately to undergo apoptosis. We have
no knowledge of the status of hormone receptors or
translocators. The suggestion is that the autophagy
is a survival mechanism carried beyond its limits.
Typically, autophagy is a slower process than
apoptosis. In cell culture, when apoptosis is blocked
and cells are subjected to challenge, they manifest
substantial autophagy and die somewhat later than
they would have died by apoptosis. One gets the
impression that autophagy, an apparently evolution-
arily older and more general process, is less efficient,
slower and less certain than apoptosis as a means of
killing cells, but it will kill cells.
This image is relevant to the clinical world
because by this interpretation the issue is to explain
the failure of the cell to survive in a milieu in which
other cells do very well. Death, perhaps conventionally
Fig. 1 The very late appearance of characteristics of apoptosis in metamorphosing insect cells. Upper row: appear-
ance of lysosomes during the involution of the salivary gland of Drosophila, which in our hands has completely col-
lapsed by 13 hrs after the beginning of puparium formation. Monodansylcadaverine detects no resolvable organelles
prior to onset of metamorphosis, but by 6 hrs there are numerous perinuclear autophagic vacuoles (arrows) and by 
9 hrs the vacuoles fill the cytoplasm (three figures on left). Lysotracker red ® detects modest activity by 9 hrs and large
autophagic vacuoles by 12 hrs. Middle row: By 3 hrs into metamorphosis, the fine filamentous actin network, detected
by rhodamine phalloidin, has given way to fine granular clumps of actin, which become more pronounced by 9 hrs. By
10 hrs the actin is in vacuoles that appear to be lysosomes, or clustered near the cell membranes. Lower row: Evidence
for apoptosis occurs only very late. Both exteriorization of phosphatidylserine as detected by annexin V (left two pan-
els) and appearance of TUNEL-positive nuclei (right two panels) occur after the 11th hr. We also confirmed the pres-
ence of caspase-positive granules at 12 hrs but, failing an interpretation of the significance of the granules, we with-
hold an interpretation. From doctoral research of Farhan S. Khan.
J. Cell. Mol. Med. Vol 11, No 6, 2007
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by apoptosis, is the product of the struggle and,
though the point of no return may (or may not) repre-
sent an important clinical turning point, the bigger
clinical effort is likely to be to prevent the cell from
approaching the threshold. In other words-and this
may be the case for chronic conditions such as neu-
rodegenerative disease-cells may be agonizing for
prolonged periods, and relieving the stress may be
the means of having the most profound impact.
Many publications ignore the fact cells can live
and die without cell death machinery. The caricature
version of this argument is that one can pour acid
onto a cell or place it in hypotonic medium, and it will
expire without the assistance of caspase-3 or other
enzymes, in a form of death commonly known as
necrosis. However, stepping back from the carica-
ture, it should also be self-evident that certain types
of stresses will kill cells even if apoptosis is blocked.
Thus, cells poisoned with metabolic inhibitors,
cytoskeleton disrupters, inhibitors of DNA synthesis
or replication, inhibitors of RNA or protein synthesis,
strong oxidants or other materials, will not survive.
For most cells examined in culture, apoptosis is the
preferred physiological response to stress but the
cells can also undergo autophagy and, failing that,
invoke other cell-destructive activities, or ultimately
lyse. One’s interpretation of the result of the experi-
ment depends very much on how one measures via-
bility – exclusion of trypan blue or certain fluorescent
molecules, failure to activate caspase 3 or extrude
phosphatidyl serine, morphological appearance of
the cell or its nucleus, failure to fragment DNA as
measured by electrophoresis or TUNEL staining or
ability to proliferate. Another operational element is
the timing of the experiment: autophagy is often
slower than apoptosis, and an injured cell may fail to
undergo apoptosis, thus appearing viable for a few
hours after it should have died; but it might well die
through alternative pathways a few hours later. Quite
frequently statements in the literature assume that
short-term apparent survival translates into long-
term survival. If it does not, the clinical expectation
may change considerably.
Note that we are avoiding the term ‘autophagic cell
death’. Although this term has been popular and
does describe a type of cell death characterized by
intense autophagy of the cytoplasm, it is much less
certain that a cell can be killed by autophagy. Indeed,
cells dependent on trophic hormones can atrophy
and become quiescent, to the extent of shrinking to
an inactive nucleus surrounded by token cytoplasm
[36–40]. This shrinkage may involve autophagy or
other proteolytic processes. These atrophic cells are
alive, as may be demonstrated by returning their
trophic factors. There is as yet no clear experimental
evidence that the autophagy or proteolysis manifest
by these cells differs in any meaningful way from the
autophagy or proteolysis leading to the death of the
cell. Rather, a different scenario seems possible. It is
perhaps most clearly described for the case of insect
larval tissues at metamorphosis described above.
These tissues typically undergo a highly autophagic
death while the adult tissues are rapidly growing.
Thus, one might suggest the following scenario: The
hormones that induce the growth of the adult, or imag-
inal, tissues render the larval tissues – by unknown
means, perhaps relating to receptors or transporters
of hormones or substrates – insensitive or unrespon-
sive to hormonal activation or uptake of nutrients. In
the absence of sufficient effective nourishment
(remember that the imaginal cells are thriving in the
same hemolymph or extracellular fluid) the cells
undertake the normal physiological process of con-
suming their own resources. They gradually dwindle
but, unlike the case of the atrophic tissue, they 
cannot maintain equilibrium at idle speed (even in
atrophic tissue, a substantial number of cells die) and
ultimately they reach a point of no return, perhaps
when they have consumed even their mitochondria.
At this point they die, perhaps by apoptosis. In this
optic, autophagy is a survival mechanism that ulti-
mately runs out of steam, and the question is why the
cell is unresponsive.
The response of a cell depends
heavily on its history,
lineage and current status 
A typical laboratory experiment to study apoptosis is
conducted on a cell line – that is, a malignant strain
of cells selected for continual growth in a Petri dish –
exposed to an apoptosis-inducing situation in a
medium containing approximately 1% serum. If one
asks why the cell is not cultured in a medium more
closely approximating the physiological extracellular
medium, approximately 10% serum, one learns that
‘you don’t get very good apoptosis in 10% serum’. In
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other words, apoptosis is studied most effectively
only in severely stressed cells. This anecdote is rele-
vant to the clinical situation in that typically, well-
nourished, trophic factor-rich cells are not easily led
into apoptosis. The most appropriate interpretation of
this observation is that, though the pathway to apop-
tosis may be rather clean and linear, either the initia-
tion of the pathway or its progress is subject to far
more controls and influences than we have seriously
considered. For instance, viruses have a vital interest
in the survival of their host cell. At first, they need the
cell to survive in order to exploit its resources to build
more virus. Later, many viruses require rupture of the
cell so that they can disperse. Meanwhile, it is in the
interest of the organism to detect infection and to
destroy the cell in a manner that also destroys the
virus – apoptosis – as quickly and efficiently as pos-
sible. It is thus not surprising that the bulk of pro- and
anti-apoptotic molecules that we know are either viral
or cell anti-viral materials. Viruses adapt many strate-
gies, ranging from rapid killing of cells to full inhibition
of host-activated cell death [41]. Some viruses
induce the death of cells as soon as synthesis and
packaging are complete, allowing the virus to escape
and continue to spread [42]. Other viruses co-opt
host defences, maturing by use of death-associated
eukaryotic proteases [43]. Others provoke destruc-
tion of B cells or helper cells, thus evading host
defences [44]. Many oncogenic viruses inhibit cell
death so effectively that mitosis surpasses apopto-
sis, allowing the tumour to grow and maximizing viral
propagation [45].
Many other metabolic and lineage- or history-
derived components affect the sensitivity of cells to
pro- or anti-apoptotic stimuli. Kroemer, Golstein and
others have recently been reflecting on the interac-
tions between autophagic and apoptotic processes
and, in a series of eloquent and carefully reasoned
papers, argue that the interactions are extremely cir-
cumstance-dependent. Thus, for instance, autophagy
may eliminate damaged mitochondria, preventing
escape to the cytoplasm of cytochrome C, apoptosis-
inducing factor and other products; or it may termi-
nate the production of reactive oxygen species,
which could oxidize membranes; or it may eliminate
mitochondria, leading to energy depletion; or lysoso-
mal or other proteases may activate apical or execu-
tioner caspases; or these proteases may destroy
caspases or other activating components of apopto-
sis, thus blocking apoptosis [46, 47]. Clearly, we have
much to learn about the intermediary metabolism of
threatened cells.
Proteins now assumed to be cell
death proteins may in fact have
‘day jobs’ or multiple functions
not appreciated by the researcher
or physician
When a function is identified for a novel protein, we
have an unfortunate tendency to assume that we
understand the role of the protein and its ‘biological
purpose’. But we may be wrong. Larger proteins may
have several domains, not all of which are identified.
Thus a protein might bind another protein, affecting
the function of the latter. But the first protein might
also have a hydrophobic domain or a nuclear local-
ization signal. Does this mean that it transports the
second protein into the nucleus, or binds it to a cell
membrane? Does its binding to a membrane affect
the motility of the cell, or its ability to pinocytose,
phagocytose or fuse organelles? There are now
many examples of proteins with clear physiological
functions that have been discovered to perform other
very important but distinctly different other physiolog-
ical functions, often contingent on their transport to a
new intracellular or extracellular location.
This issue may be defined by asking, what is the
‘day job’ of caspases? Caspases were proteases
before they were drafted into service as killers of
cells. Some of the caspases, notably interleukin-con-
verting enzyme, function as immune system effec-
tors rather than cell death enzymes. It seems improb-
able that the entire panoply of caspases, caspase
activators and caspase inhibitors floats around the
cell only to function at one final instant in the life of
the cell. Such a hypothesis is supported by the
observation of the pleiotropic effects of caspases. We
now know that caspases appear to be involved in dif-
ferentiation of erythrocytes and lens fibres, prolifera-
tion of T lymphocytes, cell migration and sperm dif-
ferentiation [48–50]. Most of the functions of caspas-
es have been defined in terms of apoptosis, through
which they were first recognized, but the enzymes
are typically present, though inactive, in viable cells,
and activation leads to the demise of the cell. Is it
J. Cell. Mol. Med. Vol 11, No 6, 2007
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truly reasonable to assume that they play no role in
the physiology of the cell other than to wait for a seri-
ous threat to the cell? It seems far more likely that
one or more initiator or executioner caspases might
be activated in very controlled circumstances to fulfil
a very different role, or that a pro-caspase might
interact with another protein, sequestering it or other-
wise affecting the biological activity of the protein; or
caspases or interacting molecules might be trafficked
from one location to another, limiting the substrates
that they could attack. Such an interaction might lead
to phenotypes that have no immediate or obvious
connection to cell death, as has been reported for
several caspase knockouts [51–57]. In another
example, inhibition of caspases leads to a pro-
nounced notochordal deformation in zebrafish
embryos (Fig. 2).
Some promise for the future?
In spite of the frustrations of the earlier and cruder
efforts, there is growing evidence that apoptosis-
based therapy will join the medical armamentarium.
First, the development of antibodies designed to initiate
cell death pathways in specific cells or circumstances
[58–62] is likely to lead to specifically targeted means
of attacking cancer cells, an approach that promises 
far lower general toxicity than most chemotherapy.
Second, for acute situations short-term general
blockage of apoptosis may still prove valuable
[63–66]. Third, recognition of alternative forms of cell
death has led to approaches to address cell death on
a broader scale than narrowly as apoptosis [67–69].
To conclude, the eras of cell culture and molecular
biology have been marvellous and have taught us far
more than we ever dared to hope to know about the
molecular interactions that drive the lives of cells.Yet
there is still something missing, something that eludes
us even when we know the shapes, sequences, and
interactions of molecules. An image of where we
might be going, and what we might need, is that of
the systems engineer—that we might be going, not
smaller, more micro and more nano, but to a larger
scale. A systems engineer tries to understand the
components of a large complex, for instance a bridge
or airplane, but more importantly, he or she attempts
to picture how it all works together: how unevenly dis-
tributed weight, vibrations, wind, metal fatigue, sub-
stratum strength and flexibility, etc, all interact to
determine the stability of the structure. Though even
the simplest cell is vastly more complex than a
bridge, we will have to develop algorithms by which
we can envision a cell not as a static or acutely
changing mix of components, but as a complex of
dynamic and mobile interacting components, some
of which are sufficiently stable or long-lived to bear
witness to the history and lineage of the cell, others
Fig. 2 Phenotype resulting from application of the pan-caspase inhibitor, zVAD.fmk, to zebrafish embryos. The noto-
chord (No) is longer than normal and consequently buckles, leading to severe deformity of the embryo. We have not
been able to establish that the increased size results from failure of cells to die or directly from the inhibition of cas-
pases. Ey: eye; Yk: yolk. From doctoral research of Nathaniel Abraham.
1222 © 2007 The Authors
Journal compilation © 2007 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
of which reflect the immediate status of the cell, and
which interact across distances and pathways that
we are not currently considering. This is a vastly larg-
er goal than we can hope to achieve immediately, but
even the most modest access will help us to better
target, and therefore control, cell death. As the hun-
dreds of thousands of publications attest, cell death
is a medically urgent topic, and movement to the next
level should cross the clinical horizon.
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